Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CoLucid sells $2mm in convertible notes to support lead migraine candidate; adds $1.5mm and $4mm

Executive Summary

To move its neutrally acting migraine candidate lasmiditan into Phase III trials, CoLucid Pharmaceuticals Inc. (neurological disorders) has raised $2mm out of a potential $6.5mm in a convertible notes sale to seven investors.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies